| Literature DB >> 33983589 |
Abstract
Monitoring of patient and tumor during chemotherapy is important to determine whether the chemotherapy is effective to the patient. Variants affect drug enzyme activities and altered enzyme activities can be potential predictors for chemotherapeutic agents including cyclophosphamide and paclitaxel. Response to chemotherapy is primarily based on somatic mutations but germline variants may predict cancer cell sensitivity to chemotherapeutic agents. Furthermore, patient's genetic variation of immune system was reported to be associated with drug response and toxicity. Recently, the somaric and germilne genomic variation influences the pharmacokinetics of chemotherapy and these variation can be biomarkers for chemotherapy.Entities:
Keywords: Biomarkers; Breast oncology; Cancer cell sensitivity; Chemotherapy; Pharmarcogenetic
Mesh:
Substances:
Year: 2021 PMID: 33983589 DOI: 10.1007/978-981-32-9620-6_19
Source DB: PubMed Journal: Adv Exp Med Biol ISSN: 0065-2598 Impact factor: 2.622